The aim of this study was to investigate the effects of acute, methionine-induced hyperhomocysteinaemia on endothelial function of skin microcirculation in diabetic compared with non-diabetic persons. Endothelial-and non-endothelialdependent vasodilatation of the skin microcirculation were evaluated in 20 persons with type 2 diabetes (59.95±2.36 years old) and 24 age-and gender-matched controls using laser Doppler flowmetry, during fasting and four hours after 0.1 g/kg methionine-induced acute hyperhomocysteinaemia. Methionine loading caused a comparable increase of homocysteine in the two groups. Four hours after induction of acute hyperhomocysteinaemia, endothelial-dependent vasodilatation (acetylcholine effect) was lower in the diabetic patients compared with the controls ([mean±SEM] 8.09±1.18-fold increase in diabetic patients vs. 11.11±1.33-fold increase in controls, p=0.027). The same was observed for the endothelial-independent vasodilatation (sodium-nitroprusside effect, 7.55±0.80-fold increase in the diabetic patients vs. 12.19±1.26-fold increase in controls, p=0.008). Acute hyperhomocysteinaemia causes a decreased response of both endothelial-dependent and endothelial-independent vasodilatation of the skin microcirculation in diabetic compared with non-diabetic persons. These alterations might contribute to the vascular complications of hyperhomocysteinaemia in diabetes, and especially the microvascular ones.
Introduction
Homocysteine (Hcy) is a sulphur-containing intermediary amino acid formed by the conversion of dietary methionine to cysteine. Elevations in plasma Hcy are common, occurring in 5% to 7% of the population. 1 Mounting evidence has now accumulated suggesting that hyperhomocysteinaemia (HHcy) is an independent risk factor for atherosclerotic vascular disease 2 and for recurrent venous thromboembolism, 3 although intervention studies unequivocally showing that useful reduction of Hcy by folate/vitamin B supplements are lacking. 4 It is very well established also that type 2 diabetes mellitus (T2DM) patients are at increased risk for macrovascular 5 as well as for microvascular complications. 6 HHcy has been shown to be a stronger risk factor in T2DM patients than in those without diabetes, and has been thought to exert a synergistic effect with diabetes in accelerating the atherosclerosis process. 7 Microvascular complications (especially nephropathy) have been noted to be associated with Hcy levels in T2DM patients as well. 8 which is associated with very high (usually > 100 μmol/L) Hcy levels, 11 as well as in association with less markedly elevated plasma Hcy levels, more relevant to the general population. 12, 13 Oral methionine loading, causing acute HHcy, can be used as a diagnostic test to identify individuals who show an exaggerated rise in Hcy levels and endothelial dysfunction. 14 There are various ways for assessing endothelial function. It can be assessed either in the macrocirculation (in resistance conduit vessels such as the brachial artery, through its response to shear stress, a process called 'Flow Mediated Vasodilatation' [FMD] 15 ), or in the microcirculation (for example through the laser Doppler flowmetry of the skin microvasculature, 16 using the iontophoresis of vasoactive substances through the skin 17 ).
Previous studies have examined the influence of HHcy, both chronic, 12, 13 as well as acute, methionine-induced, 14, [18] [19] [20] [21] on endothelial function in healthy persons. The literature concerning the effects of HHcy on endothelial function in diabetes is scarce though, and mainly restricted to the macrovasculature. 22 The effects of acute HHcy on endothelial function of the skin microcirculation in diabetic patients have not been studied so far.
Thus, the aim of the present study was to examine the effects of acute, methionine-induced hyperhomocysteinaemia on endothelial-dependent and endothelial-independent vasodilatation of the skin microcirculation in type 2 diabetes patients compared with non-diabetic controls.
Patients and methods
The study population included 20 T2DM patients (mean age [±SEM] 59.9±2.36 years, diabetes duration 7.7±5.1 years) and 24 age-and gender-matched, non-diabetic control persons (58.4±2.23 years). Controls were non-diabetic relatives of non-diabetic in-patients of a university hospital. People with hypo/hyperthyroidism, those diagnosed with cardiovascular disease (history of myocardial infarction, angina pectoris, cerebrovascular accident and/or peripheral vascular disease) and pregnant women were excluded. Patients and controls had no extra vitamin intake or medications interfering with the metabolism of folate or vitamin B6, such as methotrexate, anticonvulsants or theophylline during the four weeks prior to the study. Medications that could affect endothelial function, such as ACE-inhibitors and statins, were stopped 10 days before the test. Written informed consent was obtained from all participants. The study was carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000 and was approved by the participating hospital's ethics committee.
All patients had a complete screening physical examination to assess for the presence of microvascular (retinopathy, nephropathy and neuropathy) and macrovascular complications before inclusion into the study. Nephropathy was evaluated by an albumin/creatinine ratio in a morning spot urine sample. Patients were classified as normal (< 30 mg/g creatinine), as having microalbuminuria (30-300 mg/g creatinine) and overt proteinuria (> 300 mg/g creatinine). Current smokers were defined as participants who smoked at least one cigarette per day; never smokers as those who had never smoked in their life; and former smokers as those who had stopped smoking > 1 year previously.
Study protocol
Each patient was studied in the morning and had been asked to refrain from smoking and from drinking coffee on the day of the study. Weight, height, waist circumference and blood pressure (the mean of the last two out of three measurements using an automated Omron M5 device) were recorded.
Laboratory measurements were performed in the supine position, after an acclimatisation period of 30 min, in a temperature controlled room (23±1ºC). Microvascular endothelial function was assessed in the fasting state and 4 h after an oral methionine load (0.1 g/kg body weight) to induce acute hyperhomocysteinaemia. L-methionine powder (Scientific Hospital Supplies) was dissolved in 200 ml of orange juice. Endothelial function of the skin microcirculation was assessed using the laser Doppler technique, combined with iontophoresis of vasoactive substances (acetylcholine [Ach] and sodium nitroprusside [SNP]) through the skin, both at baseline (fasting state) and 4 h after the methionine load. Ach, an endothelium-dependent vasodilator, acts via release of nitric oxide (NO) from the endothelium, whereas SNP causes endothelial-independent vasodilatation, acting directly on the smooth muscle cells, as a direct NO donor. 23 Protocols described in the literature using laser Doppler flowmetry combined with iontophoresis are different in design and some are complicated and time consuming. [24] [25] [26] In the present study, the protocol by Morris et al. 24 was chosen, since it has been used and validated in different populations. 27, 28 In brief, after a 30-min initial acclimatisation, the flexor surface of the right forearm was gently cleansed using alcohol and then swabbed with de-ionised water. A laser Doppler instrument (Periflux model PF2, wavelength 780 nm) and a micropharmacology system (Perilont) were used for non-invasive and continuous measurement of perfusion changes during vascular provocations in the skin (Perimed AB, Jarfalla, Sweden). A drug delivery electrode was incorporated in the head of the laser probe. The probe temperature was standardised to 32 o C during drug tests. Flux was recorded at baseline and after application of increasing doses of Ach or SNP by iontophoresis and expressed in arbitrary perfusion units (PUs).
The drug delivery electrode was filled with 140 μl Ach 1% (Sigma Chemicals, St Louis, MO, USA) or SNP 1% (Sigma Chemicals) and was attached with the laser probe to the volar surface of the right forearm. A control standard probe was placed 4 cm laterally from the drug delivery electrode. Meticulous care was taken to avoid any underlying veins, freckles and hairs on the skin. Because of the heterogeneity of skin blood flow, meticulous care was also taken to select spots on the skin with similar baseline perfusion during the various phases of the tests. Examinations were performed by the same trained examiner and results were stored on a personal computer and analysed offline. Ach (1%) was delivered using an anodal current: 7×0.1 mA (milliampere) for 20 s, followed by 1×0.2 mA for 20 s, with a 60-s interval between each dose to produce a cumulative dose-response curve (total charge 18 millicoulombs -mC). Forearm skin erythrocyte flux was recorded immediately before the start of iontophoresis and after each period of drug application. Using a new delivery electrode, 1% of SNP was delivered using a cathodal current: 2×0.1 mA for 20 s, followed by 1×0.2 mA for 20 s with 180-s interval between each dose (total charge 8 mC). The order of Ach and SNP delivery was randomised. Both chemicals were freshly prepared (dissolved in de-ionised and double-distilled water) immediately prior to administration and SNP was kept in the dark. The electric current strengths were well tolerated by all subjects. Endothelium-dependent (Ach-induced) vasodilatation was expressed as the percentage increase of skin perfusion over baseline using the first five measurements only (baseline and four current charges), to avoid the effects of the high current charges at later iontophoresis periods, as has been shown in the past. 24 Endothelium-independent (SNP-induced) vasodilatation was expressed as the percentage increase of skin perfusion over baseline.
The within-subject coefficient of variation (CV) for the measurements, evaluated in nine subjects in the study, was 23%.
Blood chemistries
Blood samples were drawn before and four hours after administration of methionine (after microvascular function studies had been performed). Blood samples for Hcy measurements were collected into EDTA tubes, centrifuged immediately and stored at -80ºC until assay, whereas the rest of the tests were performed immediately. Total plasma Hcy levels were measured by automated high-performance liquid chromatography (HPLC). Lipid profiles and basic clinical chemistry parameters were measured by standard clinical chemistry methods. Low density lipoprotein (LDL) cholesterol was calculated using the equation of Friedewald et al. 29 The glomerular filtration rate (GFR) was calculated using the equation of Cockroft and Gault. 30 Insulin resistance was calculated using the Homeostasis Model Assessment (HOMA) index. 31 
Statistical analysis
Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test. Data not normally distributed were log-transformed for analysis. Data normally distributed are presented as mean±SEM, while qualitative variables are presented as absolute and relative frequencies (%). Baseline comparisons between groups were performed using independent samples t-test for normally distributed data or Wilcoxon Mann-Whitney Test for non-normally distributed data. Pearson correlation coefficients were calculated where appropriate. Chi-squared test was used to analyse qualitative variables. Assessments of the effects of Ach or SNP on skin microvascular dilatation between the two groups of participants were made using two-way analysis of variance (ANOVA) for repeated measures, taking into account the baseline and post-methionine phases of the experiments and using the first five measurements only for the Ach effect, as previously suggested. 24 Results are expressed as percentage increase of flux compared with baseline values. All reported p-values are from two-sided tests and compared with a significance level of 5%. Data were analysed using the Statistical Package SPSS (version 16.0).
Results
Participants' demographic and clinical characteristics are summarised in Table 1 . The two groups were similar regarding age and blood pressure. As expected, fasting plasma glucose, HbA1c and HOMA insulin resistance index values were higher in the diabetic patients and the HDL-cholesterol levels lower, compared with the controls. The diabetic patients were more obese as well.
Fasting Hcy levels were not different between the two groups. Oral methionine loading caused a similar, significant increase in plasma Hcy levels, by around three-fold, in both groups, four hours later (Table 1 ). There was no correlation between fasting Hcy and insulin levels (either in the patients with diabetes or in the controls), as well as between Hcy levels and creatinine clearance. A significant positive correlation was found between fasting Hcy levels and age only in the patients with diabetes (r=0.47, p=0.037).
Microvascular laser Doppler responses to acetylcholine and sodium nitroprusside
When examining the effects of the vasoactive substances on the skin microcirculation between the two groups (diabetic patients and controls), it was noted that in the fasting state, iontophoretically applied Ach caused a similar vasodilator response in both diabetic patients and control subjects (increase in flux by 7.55±0.96 fold vs. 8.64±0.94fold, respectively [two-way ANOVA for repeated measures p=0.174]) ( Figure 1A) , whereas, after methionine-induced HHcy 4 h later, Ach application caused a significantly more blunted vasodilator response in the diabetic patients compared with the controls (8.09±1.18-fold increase in diabetic patients vs. 11.11±1.33-fold increase in controls, p=0.027) ( Figure 1B) . Adjustment for body mass index (BMI) did not significantly alter the results (p=0.034). When only the maximum percentage increases of Ach-induced vasodilatation in the fasting and the post-methionine periods were compared vs. the baseline values, by t-test, no statistically significant differences were observed.
Similarly, iontophoretically applied SNP in the fasting state caused an analogous vasodilator response both in diabetic patients and in control subjects (11.09±1.48-fold increase in patients with diabetes vs. 12.74±1.39-fold increase in controls [two-way ANOVA for repeated measures p=0.642]) (Figure 2A) , whereas after methionine-induced HHcy 4 h later, SNP application caused a significantly more reduced vasodilator response in the diabetic patients compared with the controls (7.55±0.80-fold incre-ase in diabetic patients vs. 12.19±1.26-fold increase in controls, p=0.008) ( Figure 2B ). Again, adjustment for BMI did not alter the results (p=0.014). When only the maximum percentage increases of SNPinduced vasodilatation in the fasting and the post-methionine periods were compared vs. the baseline values by t-test, it was found that there was a statistically significant difference (lower maximum vasodilatation) in the diabetic patients compared with the controls only in the post-methionine loading phase (7.55±0.80-fold increase in diabetic patients vs.
12.19±1.26-fold increase in controls, p=0.005 [by t-test]).
Baseline values (before methionine loading) were not different between the two groups by t-test.
Discussion
This study suggests that acute, methionine-induced hyperhomocysteinaemia causes more reduced microvascular vasodilator effects (both endothelial-and non-endothelialdependent) in T2DM patients compared with non-diabetic controls ( Figures 1B and 2B ). Previous studies have examined the influence of HHcy, both chronic, 12, 13 as well as acute, methionine-induced, 14,18-21 on endothelial function in healthy persons. The literature concerning the effects of HHcy on endothelial function in diabetic patients is scarce though, and restricted only to the influence of chronic HHcy on the macrovasculature. 22 Events occurring in the macrovasculature though are not necessarily reproduced in the microvasculature, since endothelial dysfunction in conduit vessels and impaired cutaneous microvascular responses to reactive hyperaemia were shown not to correlate, and might at least partly develop independently due to several differences in their pathogenesis. 32 To our knowledge, this is the first study that examines the effects of acute, methionine-induced HHcy on microvascular function in diabetic patients.
In the two previous studies that examined the influence of acute HHcy on microvascular function in healthy adults, 18, 19 contradictory results were obtained. In the study by Davis et al. on 14 healthy male subjects, 18 no significant effect of acute HHcy on microvascular vasodilator function was noted, either with Ach or with SNP iontophoretic administration. On the contrary, Abahji et al. 19 found that acute HHcy led to a significant decrease in Ach-stimulated skin microvascular (as well as macrovascular [estimated by FMD of the brachial artery]) vasodilatation in 11 healthy adult subjects. No significant response of SNP-stimulated vasodilatation on either vascular system was found and also no correlation between the magnitude of endothelial dysfunction in the two vascular territories.
The novel finding of our study is that T2DM patients had a significantly more blunted vasodilatation after acute HHcy, both endothelial-and, mainly, non-endothelial-dependent, than the controls. These functional alterations may contribute to the observed heightened cardiovascular risk seen in T2DM patients with HHcy 7,33 as well as to the increased microvascular risk seen in both type 1 34 as well as type 2 diabetes patients 8 with high Hcy levels.
The mechanisms by which HHcy induces endothelial dysfunction are incompletely defined. 10 One consistent finding from studies of experimental HHcy is impairment of vasodilatation mediated by endothelium-derived NO. 35 NO is a potent vasodilator that is produced by the endothelial isoform of nitric oxide synthase (eNOS) in response to physiological stimuli, and is a major mediator of endotheliumdependent relaxation. 36 Expression of eNOS does not appear to be decreased during HHcy, and vasodilator responses to nitroprusside or nitroglycerin are preserved in animal models of HHcy, 35 suggesting that sensitivity of vascular muscle to NO is relatively normal in these (non-diabetic) conditions. Our study demonstrated that acute HHcy caused a significant impairment of both smooth muscle (endothelial-independent) vasodilator responses to exogenous nitrate (SNP) on the microvascular circulation as well as to the endothelialdependent vasodilatation in diabetic patients. It is possible that the combination of the glycaemic milieu of diabetes with the direct effects of acute HHcy is responsible for these effects. Indeed, chronic hyperglycaemia has been known to adversely affect endothelial function 37 and diabetes mellitus has been independently associated with both endothelialand non-endothelial dependent (smooth muscle) vasodilator dysfunction in persons at risk for atherosclerosis. 38 Advanced glycosylation end products (AGEs), the glucose-derived moieties that form nonenzymatically and accumulate on long-lived tissue proteins, have been implicated in many of the complications of diabetes. AGEs have been shown to quench NO activity in vitro and in vivo, 39 and thus contribute to endothelial dysfunction in diabetes.
Fasting Hcy concentrations were not different between diabetic and non-diabetic control subjects in the present study. Plasma Hcy levels have been reported to be normal, reduced or elevated in patients with diabetes mellitus, 40 depending on age and renal function 41 or the circulating insulin concentrations. 42 No correlation was found between insulin levels or creatinine clearance and Hcy concentrations in the present study though.
Our study has several limitations: first, microvascular flow measurements were performed using a single probe on the skin surface, thus producing heterogeneity due to spatial and temporal variations of the laser Doppler flux. This is indicated by within-subject CVs of 23% in our study, as well as in others (reported around 25-30%). 19, 26 Meticulous care was taken, however, in our study to select spots on the skin with similar baseline perfusion fluxes during the various phases of the tests and to avoid any underlying veins, freckles and hairs on the skin. This was actually accomplished, since the baseline absolute PU fluxes were not different between diabetic patients and non-diabetic controls at the fasting and post-methionine phases (baseline flux before methionine administration: 9.54±1.42 PUs in diabetic patients vs. 11.20±1.89 in controls for Ach; and 8.66±1.12 in diabetic patients vs. 7.05±0.56 in controls for SNP; baseline flux 4 h after methionine administration: 10.52±1.29 PUs in diabetic patients vs. 9.67±1.28 in controls for Ach; and 9.38±0.98 in diabetic patients vs. 7.95±0.67 in controls for SNP; all comparisons non-significant). A second limitation is that the sample size is not very big (44 participants), but is definitely much bigger than the two previous studies 18, 19 that examined the issue in healthy subjects (14 and 11 participants, respectively). A third limitation is that analyses of microvascular endothelial function were performed offline, from data stored on a computer, but were not done blinded. This might have introduced some bias. Another limitation is that the methionine challenge was performed by dissolving methionine in orange juice. One could argue that the sugar contained in the juice might have acted as a low dose glucose tolerance test and the resulting postprandial hyperglycaemia might have confounded the results of the microvascular tests. 43 No post-methionine glucose levels were measured and thus results could not be adjusted for them. But since microvascular measurements were performed four hours after the methionine oral challenge, it is very unlikely that the glucose from the orange juice would still be effective. Finally, no placebo for methionine was used in the two groups of participants to evaluate the independent order/time effects of methionine loading to cause acute HHcy. The aim of the study though was to evaluate the possible differential effects of acute HHCy on diabetic vs. non-diabetic patients and not the effects of acute HHcy in general.
In conclusion, this study has demonstrated that acute hyperhomocysteinaemia causes a reduced response of endothelial-dependent and mainly endothelial-independent vasodilatation of the skin microcirculation in diabetic persons, compared with non-diabetic ones. These changes may offer a potential mechanism for the role of homocysteine on diabetic complications, especially the microvascular ones, and should prompt further research.
